Cidara Therapeutics Takes Bold Steps in Phase 3 CD388 Development
Cidara Therapeutics, Inc. is making significant progress in the clinical development of its innovative treatment for seasonal influenza, CD388. The company has recently unveiled an expanded and accelerated plan for its Phase 3 study, showcasing its commitment to combatting the effects of seasonal flu, especially in vulnerable populations.
Details on the Phase 3 Study
According to the latest information, the Phase 3 trial of CD388 has been fast-tracked, allowing for a start six months earlier than previously anticipated. Initially expected to commence in the spring of 2026, the study will now begin by the end of September 2025, well in time for the upcoming flu season in the Northern Hemisphere. This advance is a crucial step for Cidara as it aims to establish CD388 as a safe and effective non-vaccine option for flu prevention.
Expanded Study Population
In response to feedback from the U.S. Food and Drug Administration (FDA), Cidara plans to broaden the trial's eligibility criteria. The study will now encompass adults aged 65 and older, in addition to younger individuals with specific high-risk health conditions. This decision significantly increases the potential participant pool from around 50 million to over 100 million people in the United States. Understanding the immune vulnerabilities of older adults, Cidara is addressing a significant unmet medical need.
Study Design and Objectives
The planned study will be a global, multicenter, randomized, double-blind, placebo-controlled trial. Participants will receive a single 450-milligram dose of CD388 via subcutaneous injection at the start of the flu season. The trial's primary endpoint will involve laboratory-confirmed influenza cases, elevated body temperatures, and specific respiratory and systemic symptoms. This comprehensive approach aims to gather robust efficacy and safety data for CD388.
Cidara's Commitment to Innovation
With its proprietary Cloudbreak platform, Cidara Therapeutics is pioneering the development of drug-Fc conjugate (DFC) therapeutics that target both viral infections and oncology. The lead candidate CD388 aims to provide a long-acting solution against seasonal and pandemic influenza, a much-needed intervention considering the limitations of current vaccines, especially for older populations vulnerable to flu complications.
Recent Achievements
In June 2023, CD388 received Fast Track Designation from the FDA, highlighting its potential importance in public health. The results from the Phase 2b NAVIGATE trial, announced in June 2025, have further bolstered Cidara's confidence in the drug’s efficacy. As the company prepares for the upcoming Phase 3 trial, it believes that funding from a recent financing round will fully support its development plans until completion.
Looking Forward
Dr. Jeffrey Stein, the president and CEO of Cidara Therapeutics, expressed the significance of the FDA's feedback on the Phase 3 study design. He emphasized the need for a solution that not only meets the medical needs of older adults but also accelerates participant enrollment. The company is enthusiastic about the future and is dedicated to positioning CD388 as a key player in the flu prevention arena.
Frequently Asked Questions
What is CD388?
CD388 is Cidara Therapeutics' lead candidate aimed at providing long-acting antiviral prevention of seasonal influenza for individuals, especially vulnerable populations.
What is the significance of the Phase 3 trial?
The Phase 3 trial is crucial as it aims to gather the final data needed for potential approval of CD388, making it a viable non-vaccine option for flu prevention.
How many participants will be involved in the trial?
The trial is targeting enrollment of approximately 6,000 participants across a broad demographic, including older adults and those with high-risk conditions.
When will the trial begin?
The Phase 3 trial for CD388 is set to begin by the end of September 2025, marking a six-month acceleration from previous plans.
How has FDA feedback influenced the study?
The FDA's input has led to an expanded study population and adjustments to the trial design, allowing for a more comprehensive assessment of CD388's effectiveness.
